Sex differences in thrombosis

Expert Review of Hematology

Volumn 1, Issue 1, 2008, Pages 3-8

  Nordstrom, Sarah M ^a   Weiss, Ethan J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GROWTH HORMONE; PROGESTERONE; TESTOSTERONE;

BLOOD; EDITORIAL; FEMALE; HEART INFARCTION; HUMAN; MALE; PHYSIOLOGY; SEX DIFFERENCE; SIGNAL TRANSDUCTION; STROKE; THROMBOSIS; VENOUS THROMBOEMBOLISM;

ESTROGENS; FEMALE; GROWTH HORMONE; HUMANS; MALE; MYOCARDIAL INFARCTION; PROGESTERONE; SEX FACTORS; SIGNAL TRANSDUCTION; STROKE; TESTOSTERONE; THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 79954441478     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/17474086.1.1.3     Document Type: Article

References (66)

1. Vasan RS, Larson MG, Levy D, Evans JC, Benjamin EJ. Distribution and categorization of echocardiographic measurements in relation to reference limits: the Framingham Heart Study: formulation of a height- and sex-specific classification and its prospective validation. Circulation 96, 1863–1873 (1997).
2. Rosenkranz-Weiss P, Tomek RJ, Mathew J, Eghbali M. Gender-specific differences in expression of mRNAs for functional and structural proteins in rat ventricular myocardium. J. Mol. Cell. Cardiol. 26, 261–270 (1994).
3. Huxley VH. Sex and the cardiovascular system: the intriguing tale of how women and men regulate cardiovascular function differently. Adv. Physiol. Educ. 31, 17–22 (2007).
4. Celentano A, Palmieri V, Arezzi E et al. Gender differences in left ventricular chamber and midwall systolic function in normotensive and hypertensive adults. J. Hypertens. 21, 1415–1423 (2003).
5. Becker DM, Segal J, Vaidya D et al. Sex differences in platelet reactivity and response to low-dose aspirin therapy. JAMA 295, 1420–1427 (2006).
6. Kurrelmeyer K, Becker L, Becker D, Yanek L, Goldschmidt-Clermont P, Bray PF. Platelet hyperreactivity in women from families with premature atherosclerosis. J. Am. Med. Womens Assoc. 58, 272–277 (2003).
7. Faraday N, Goldschmidt-Clermont PJ, Bray PF. Gender differences in platelet GPIIb–IIIa activation. Thromb. Haemost. 77, 748–754 (1997).
8. Woodward M, Rumley A, Lowe GD, Tunstall-Pedoe H. C-reactive protein: associations with haematological variables, cardiovascular risk factors and prevalent cardiovascular disease. Br. J. Haematol. 122, 135–141 (2003).
9. Woodward M, Lowe GD, Rumley A et al. Epidemiology of coagulation factors, inhibitors and activation markers: the Third Glasgow MONICA Survey. II. Relationships to cardiovascular risk factors and prevalent cardiovascular disease. Br. J. Haematol. 97, 785–797 (1997).
10. Lowe GD, Rumley A, Woodward M et al. Epidemiology of coagulation factors, inhibitors and activation markers: the Third Glasgow MONICA Survey. I. Illustrative reference ranges by age, sex and hormone use. Br. J. Haematol. 97, 775–784 (1997).
11. Rothwell PM, Coull AJ, Silver, LE et al. Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet 366, 1773–1783 (2005).
12. Kyrle PA, Minar E, Bialonczyk C, Hirschl M, Weltermann A, Eichinger S. The risk of recurrent venous thromboembolism in men and women. N. Engl. J. Med. 350, 2558–2563 (2004).
13. McRae S, Tran H, Schulman S, Ginsberg J, Kearon C. Effect of patient’s sex on risk of recurrent venous thromboembolism: a meta-analysis. Lancet 368, 371–378 (2006).
14. White RH. The epidemiology of venous thromboembolism. Circulation 107 (23 Suppl. 1), I4 –I8 (2003).
15. Dahlback B. Advances in understanding pathogenic mechanisms of thrombophilic disorders. Blood 112, 19–27 (2008).
16. Baglin T, Luddington R, Brown K, Baglin C. High risk of recurrent venous thromboembolism in men. J. Thromb. Haemost. 2, 2152–2155 (2004).
17. Treffers PE, Huidekoper BL, Weenink GH, Kloosterman GJ. Epidemiological observations of thrombo-embolic disease during pregnancy and in the puerperium, in 56,022 women. Int. J. Gynaecol. Obstet. 21, 327–331 (1983).
18. Wong JH, Dukes J, Levy RE et al. Sex differences in thrombosis in mice are mediated by sex-specific growth hormone secretion patterns. J. Clin. Invest. 118 (8), 2969–2978 (2008).
19. Lemini C, Jaimez R, Franco Y. Gender and inter-species influence on coagulation tests of rats and mice. Thromb. Res. 120, 415–419 (2007).
20. Nanda N, Andre P, Bao M et al. Platelet aggregation induces platelet aggregate stability via SLAM family receptor signaling. Blood 106, 3028–3034 (2005).
21. Arnlov J, Pencina MJ, Amin S et al. Endogenous sex hormones and cardiovascular disease incidence in men. Ann. Intern. Med. 145, 176–184 (2006).
22. Bushnell CD. Stroke and the female brain. Nat. Clin. Pract. Neurol. 4, 22–33 (2008).
23. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 348, 977–980 (1996).
24. Jick H, Jick S, Myers MW, Vasilakis C. Risk of acute myocardial infarction and low-dose combined oral contraceptives. Lancet 347, 627–628 (1996).
25. Grodstein F, Stampfer MJ, Goldhaber SZ et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 348, 983–987 (1996).
26. Vandenbroucke JP, Rosing J, Bloemenkamp KW et al. Oral contraceptives and the risk of venous thrombosis. N. Engl. J. Med. 344, 1527–1535 (2001).
27. Jespersen J. Plasma resistance to activated protein C: an important link between venous thromboembolism and combined oral contraceptives – a short review. Eur. J. Contracept. Reprod. Health Care 1, 3–11 (1996).
28. Rosing J, Middeldorp S, Curvers J et al. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet 354, 2036–2040 (1999).
29. Curvers J, Thomassen MC, Nicolaes GA et al. Acquired APC resistance and oral contraceptives: differences between two functional tests. Br. J. Haematol. 105, 88–94 (1999).
30. Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Female hormones and thrombosis. Arterioscler. Thromb. Vasc. Biol. 22, 201–210 (2002).
31. Vehkavaara S, Silveira A, Hakala-Ala-Pietila T et al. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb. Haemost. 85, 619–625 (2001).
32. Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 362, 428–432 (2003).
33. Deroo BJ, Korach KS. Estrogen receptors and human disease. J. Clin. Invest. 116, 561–570 (2006).
34. Couse JF, Korach KS. Estrogen receptor null mice: what have we learned and where will they lead us? Endocr. Rev. 20, 358–417 (1999).
35. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators – mechanisms of action and application to clinical practice. N. Engl. J. Med. 348, 618–629 (2003).
36. Delmas PD, Ensrud KE, Adachi JD et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J. Clin. Endocrinol. Metab. 87, 3609–3617 (2002).
37. Meier CR, Jick H. Tamoxifen and risk of idiopathic venous thromboembolism. Br. J. Clin. Pharmacol. 45, 608–612 (1998).
38. Cushman M. Effects of estrogen and selective estrogen receptor modulators on hemostasis and inflammation: potential differences among drugs. Ann. NY Acad. Sci. 949, 175–180 (2001).
39. Peverill RE. Hormone therapy and venous thromboembolism. Best Pract. Res. Clin. Endocrinol. Metab. 17, 149–164 (2003).
40. Decensi A, Maisonneuve P, Rotmensz N et al. Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation 111, 650–656 (2005).
41. Duvernoy CS, Kulkarni PM, Dowsett SA, Keech CA. Vascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial: incidence, patient characteristics, and effect of raloxifene. Menopause 12, 444–452 (2005).
42. MacLeod JN, Pampori NA, Shapiro BH. Sex differences in the ultradian pattern of plasma growth hormone concentrations in mice. J. Endocrinol. 131, 395–399 (1991).
43. Eden S. Age- and sex-related differences in episodic growth hormone secretion in the rat. Endocrinology 105, 555–560 (1979).
44. Norstedt G, Palmiter R. Secretory rhythm of growth hormone regulates sexual differentiation of mouse liver. Cell 36, 805–812 (1984).
45. Wong JH, Dukes J, Levy RE et al. Sex differences in thrombosis in mice are mediated by sex-specific growth hormone secretion patterns. J. Clin. Invest. 118, 2969–2978 (2008).
46. Udo JM, Ken KYH. Regulation of growth hormone action by gonadal steroids. Endocrinol. Metab. Clin. North Am. 36, 57–73 (2007).
47. Kelly JJ, Rajkovic IA, O’Sullivan AJ, Sernia C, Ho KK. Effects of different oral oestrogen formulations on insulin-like growth factor-I, growth hormone and growth hormone binding protein in post-menopausal women. Clin. Endocrinol. (Oxford) 39, 561–567 (1993).
48. Ho KK, O’Sullivan AJ, Wolthers T, Leung KC. Metabolic effects of oestrogens: impact of the route of administration. Ann. Endocrinol. (Paris) 64, 170–177 (2003).
49. O’Sullivan AJ, Crampton LJ, Freund J, Ho KKY. The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women. J. Clin. Invest. 102, 1035–1040 (1998).
50. Wolthers T, Hoffman DM, Nugent AG, Duncan MW, Umpleby M, Ho KK. Oral estrogen antagonizes the metabolic actions of growth hormone in growth hormone-deficient women. Am. J. Physiol. Endocrinol. Metab. 281, E1191 –E1196 (2001).
51. Leong GM, Moverare S, Brce J et al. Estrogen up-regulates hepatic expression of suppressors of cytokine signaling-2 and -3 in vivo and in vitro. Endocrinology 145, 5525–5531 (2004).
52. Leung KC, Doyle N, Ballesteros M et al. Estrogen inhibits GH signaling by suppressing GH-induced JAK2 phosphorylation, an effect mediated by SOCS-2. PNAS 100, 1016–1021 (2003).
53. Greenhalgh CJ, Rico-Bautista E, Lorentzon M et al. SOCS2 negatively regulates growth hormone action in vitro and in vivo. J. Clin. Invest. 115, 397–406 (2005).
54. Flores-Morales A, Greenhalgh CJ, Norstedt G, Rico-Bautista E. Negative regulation of growth hormone receptor signaling. Mol. Endocrinol. 20, 241–253 (2006).
55. Miquet JG, Sotelo AI, Bartke A, Turyn D. Suppression of growth hormone (GH) Janus tyrosine kinase 2/signal transducer and activator of transcription 5 signaling pathway in transgenic mice overexpressing bovine GH. Endocrinology 145, 2824–2832 (2004).
56. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Buller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 346, 1593–1596 (1995).
57. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 346, 1589–1593 (1995).
58. Sare GM, Gray LJ, Bath PM. Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis. Eur. Heart. J. 29 (16), 2031–2041 (2008).
59. Choi BG, McLaughlin MA. Why men’s hearts break: cardiovascular effects of sex steroids. Endocrinol. Metab. Clin. North Am. 36, 365–377 (2007).
60. Miljic D, Miljic P, Doknic M et al. Changes in prothrombin and activated partial thromboplastin time during replacement therapy with human recombinant growth hormone in growth hormone deficient adults. Hormones (Athens) 5, 187–191 (2006).
61. Sood R, Kalloway S, Mast AE, Hillard CJ, Weiler H. Fetomaternal cross talk in the placental vascular bed: control of coagulation by trophoblast cells. Blood 107, 3173–3180 (2006).
62. Kovalevsky G, Gracia CR, Berlin JA, Sammel MD, Barnhart KT. Evaluation of the association between hereditary thrombophilias and recurrent pregnancy loss: a meta-analysis. Arch. Intern. Med. 164, 558–563 (2004).
63. Brenner B, Grabowski EF, Hellgren M et al. Thrombophilia and pregnancy complications. Thromb. Haemost. 92, 678–681 (2004).
64. Towfighi A, Saver JL, Engelhardt R, Ovbiagele B. A midlife stroke surge among women in the United States. Neurology 69, 1898–1904 (2007).
65. Campbell CL, Smyth S, Montalescot G, Steinhubl SR. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA 297, 2018–2024 (2007).
66. Kent DM, Price LL, Ringleb P, Hill MD, Selker HP. Sex-based differences in response to recombinant tissue plasminogen activator in acute ischemic stroke: a pooled analysis of randomized clinical trials. Stroke 36, 62–65 (2005).